Abstract
Abstract Background In this paper, we report the descriptive, epidemiological, virologic and clinical features of the response to the investigational antiviral Tecovirimat, during the last Human Monkeypox outbreak in New City. Methods This is a retrospective observational study, based on data obtained from a convenient sample of patients evaluated for monkeypox infection at Harlem Hospital Infectious Diseases Clinic, from June 30th 2022 to September 1st 2022. Outbreak analysis was completed using grid-like/mapping approach to evaluate the distribution of the lesions. Statistical analysis was conducted using binary logistic and Chi-square analysis. Mapping of lesions Results 44 patients were included in the study 16 (36%) patients were immunocompromised with HIV with an absolute CD4 count ranging from 22 to 1048. Of the 44 patients, 30 (68%) were prescribed oral tecovirimat. Follow up showed that 13(43.3%) and 3 (3%) patients who received tecovirimat had complete resolution of symptoms at 7 days and 14 days respectively. 4 (9%) patients were lost to follow up and 2 (4.5%) were hospitalized for worsening symptoms. Overall medication was well tolerated with no reported events that were felt to be related to the medication. Symptoms grid mapping showed a higher prevalence of lesions at the genital and rectal area, highly significant in the treatment group. We were not able to establish a significant statistical correlation between HIV status/CD4 count and resolution of symptoms. However statistical analysis showed a significant positive correlation between treatment with Tecovirimat and resolution of symptoms at 14 days (P = 0.047). Conclusion The results published in the abstract are mostly descriptive of the sample and the general management including the use of Tecovirimat. Most patients who received tecovirimat had a complete resolution of symptoms n= (53%) at 14 days. It is not clear whether this difference was attributable to the efficacy of the treatment versus the natural course of disease. Indeed, several patients in the non-treatment group were lost to follow up. Further studies are needed to define the effect of severe immunosuppression and the efficacy of available antiviral drugs on the course of disease. Disclosures All Authors: No reported disclosures
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
